|
|
|
03 Sep 2008 |
OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Diabetes Candidate, PSN821
|
|
03 Sep 2008 |
Regeneron's ARCALYST(R) (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-Lowering Therapy
|
|
02 Sep 2008 |
ApoA-I Data Presented at European Society of Cardiology Congress
|
|
28 Aug 2008 |
Emerging diabetes drugs consider beta cell mass and function as an important target
|
|
27 Aug 2008 |
Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
|
|
25 Aug 2008 |
Phase 1b/2a Program Commences for RVX-208
|
|
24 Aug 2008 |
Telik Announces Diabestes License Agreement With Recetorbio
|
|
21 Aug 2008 |
Enobia Pharma initiates clinical testing of enzyme replacement therapy to treat Hypophosphatasia
|
|
21 Aug 2008 |
Activx Biosciences, Inc. Announces Positive Phase Ib and IIa Clinical Trial Results for KRP-104, a Flexible Dosing DPP-4 Inhibitor for Type 2 Diabetes
|
|
21 Aug 2008 |
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
|
|
14 Aug 2008 |
Abbott and AstraZeneca expand relationship to include co-promotion of CRESTOR(R)
|
|
12 Aug 2008 |
Altus Pharmaceuticals Announces Achievement of Primary Endpoint in Phase 3 Efficacy Trial of Trizytek for Cystic Fibrosis Patients with Pancreatic Insufficiency
|
|
11 Aug 2008 |
DiaMedica Enrolls First Patient in Phase IIa Clinical Trial for DM-99
|
|
07 Aug 2008 |
Ore Pharmaceuticals Acquires Rights to Develop a Second Drug Candidate from Roche
|
|
07 Aug 2008 |
Genzyme and Isis Begin Second Phase 3 Trial of Mipomersen
|
|
06 Aug 2008 |
Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
|
|
06 Aug 2008 |
Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
|
|
05 Aug 2008 |
Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis...
|
|
04 Aug 2008 |
Theratechnologies Reports on Positive Body Image Parameters at the International AIDS Conference
|
|
04 Aug 2008 |
Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
|
|
04 Aug 2008 |
Karo Bio Announces Successful Phase II Study with Eprotirome in Combination with Statin
|
|
03 Aug 2008 |
MDRNA Announces Phase 2 Trial of PYY(3-36) Does not Meet Weight Loss Endpoint
|
|
31 Jul 2008 |
AtheroGenics Reports Positive Results From ANDES Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes
|
|
29 Jul 2008 |
SemBioSys submits IND for safflower-produced insulin to U.S. FDA
|
|
28 Jul 2008 |
Amgen Announces Positive Top-Line Results for Denosumab Pivotal Postmenopausal Osteoporosis Trial
|
|
26 Jul 2008 |
Once-yearly Aclasta(R) recommended in EU to treat male osteoporosis and reduce risk of new fractures in patients after hip fracture
|
|
24 Jul 2008 |
Zelos Therapeutics Reaches Agreement with the FDA and EMEA for a Registration Study of ZT-031 for the Treatment of Osteoporosis
|
|
24 Jul 2008 |
Biodel Announces Publications Demonstrating Superior Metabolic Profile of VIAject(TM) Compared to the Rapid-acting Analog Humalog(R) and Regular Human Insulin in Healthy Volunteers and Compared to Regular Human Insulin in Patients with Type 1 Diabetes
|
|
23 Jul 2008 |
Merck & Co., Inc. (MRK)'s JANUMET (TM) Approved in the European Union for Treatment of Type 2 Diabetes
|
|
23 Jul 2008 |
Bristol-Myers Squibb and AstraZeneca Submit New Drug Application in the United States and Marketing Authorization Application in Europe for ONGLYZA(TM) (saxagliptin) for the Treatment of Type 2 Diabetes
|
|
22 Jul 2008 |
Amarin Proceeding to Phase 3 with AMR101 for Hypertriglyceridemia
|
|
19 Jul 2008 |
Galapagos announces first milestone in osteoporosis collaboration with Lilly
|
|
17 Jul 2008 |
Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU
|
|
16 Jul 2008 |
Hollis-Eden Pharmaceuticals Commences Phase II Clinical Trial with TRIOLEX(TM) (HE3286) in Type-2 Diabetes Patients; Expands Sites to Accelerate Enrollment
|
|
15 Jul 2008 |
Novo Nordisk files for regulatory approval of liraglutide in Japan
|
|
14 Jul 2008 |
Penwest Begins Phase Ia Clinical Trial of A0001, a Compound For Treatment of Mitochondrial Diseases
|
|
14 Jul 2008 |
DiaMedica Meets Primary Endpoint from Phase II DM-83 Study in Type 2 Diabetes
|
|
14 Jul 2008 |
Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
|
|
13 Jul 2008 |
Merck Sharp & Dohme (MRK) TREDAPTIVE(TM) Approved in the European Union: New Lipid-Modifying Therapy to Treat LDL-C, HDL-C and Triglycerides
|
|
09 Jul 2008 |
Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
|
|
09 Jul 2008 |
Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
|
|
08 Jul 2008 |
Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
|
|
02 Jul 2008 |
MicroIslet Provides Safety and Efficacy Data Update
|
|
01 Jul 2008 |
Palatin Technologies Announces Amendment Expanding AstraZeneca Obesity Collaboration
|
|
30 Jun 2008 |
Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)
|
|
26 Jun 2008 |
Andromeda Biotech Announces Successful Interim Results of Leading Product DiaPep 227 for Treatment of Type 1 Diabetes Phase III clinical study with DiaPep 277 will continue as planned following the Interim Analysis of Data demonstrating Safety and Efficac
|
|
25 Jun 2008 |
Osiris Therapeutics Announces $2 Million Milestone Payment for Clinical Progress of a Stem Cell Therapy for Type 1 Diabetes
|
|
24 Jun 2008 |
Novo Nordisk receives approval in the US for PrandiMet(TM)
|
|
23 Jun 2008 |
Emisphere Announces License Agreement With Novo Nordisk to Develop Oral Formulation of GLP-1 Receptor Agonists for Diabetes
|
|
22 Jun 2008 |
Merck Provides Update on U.S. Regulatory Status of MK-0524A (ER niacin/laropiprant) and MK-0524B (ER niacin/laropiprant/simvastatin)
|
| |
|
Results 1 - 50 of 957 |
